newsfilter
← Latest News
GlobeNewswire·

Minerva Announces Leadership Transition

  • Minerva Neurosciences appointed Jim O'Connor as Chief Business Officer effective April 21, 2026.
  • Geoff Race stepped down as President after 16 years with the company.
  • Race will remain with Minerva in a consultant capacity during the leadership transition.
  • The company aims to advance roluperidone through its next planned Phase 3 trial for negative symptoms of schizophrenia.
  • Jim O'Connor brings over 20 years of legal & business experience, including prior roles at Axena Health & United Technologies.
  • Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on central nervous system disorder therapies.